Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

NCT00124748 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
476
Enrollment
INDUSTRY
Sponsor class

Stopped This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals